End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.56 CNY | +0.20% |
|
-4.98% | -26.68% |
10/04 | China stocks down pressured by real estate; HK shares up | RE |
09/04 | Beijing Kawin Technology Share-Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 29.58 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.68% | 588M | - | ||
+15.85% | 121B | B+ | ||
+20.03% | 113B | B+ | ||
+17.47% | 26.02B | B | ||
-25.18% | 19.39B | B+ | ||
-19.51% | 15.91B | A- | ||
-19.24% | 15.09B | B | ||
-46.87% | 15.06B | A- | ||
+61.94% | 14.93B | C+ | ||
+6.31% | 13.85B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688687 Stock
- Ratings Beijing Kawin Technology Share-Holding Co., Ltd.